問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Hematology & Oncology

Division of Pediatrics

Division of General Internal Medicine

Digestive System Department

Changhua Christian Children's Hospital

Division of Pediatrics

更新時間：2023-09-19

顏旭亨
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

32Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏旭亨

List

54Cases

2008-06-01 - 2010-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2017-09-01 - 2019-01-03

Others

Completed
A Phase 2a, randomized, double-blind, placebo-controlled, dose-ranging, parallel group study to evaluate safety, tolerability, and pharmacodynamics of PF-05221304 administered daily for 16-weeks to adult subjects with nonalcoholic fatty liver disease

  • Condition/Disease

    nonalcoholic fatty liver disease

  • Test Drug

    PF-05221304

Participate Sites
7Sites

Terminated7Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2020-11-06 - 2023-12-26

Phase II

Completed
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3

  • Condition/Disease

    NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3

  • Test Drug

    PF-06865571PF-05221304

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2025-09-01 - 2032-10-06

Phase II/III

Active
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • Condition/Disease

    Severely Active Crohn's Disease

  • Test Drug

    Icotrokinra

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2032-01-13

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    Icotrokinra

Participate Sites
5Sites

Recruiting5Sites

2020-03-31 - 2028-01-27

Phase II/III

Active
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Guselkumab/placebo

Participate Sites
4Sites

Recruiting4Sites

2023-12-01 - 2029-08-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-09-15 - 2024-01-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2010-11-01 - 2012-06-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-04-12 - 2028-12-31

Phase II

Active
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    GS-1427

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB